# The Median Effective Dose of Remimazolam for Duodenoscopy Insertion During ERCP With Alfentanil 10µg/kg

> **NCT04969068** · PHASE4 · UNKNOWN · sponsor: **Tianjin Nankai Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Anesthesia

## Interventions

- **DRUG:** Remimazolam

## Key facts

- **NCT ID:** NCT04969068
- **Lead sponsor:** Tianjin Nankai Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-23
- **Primary completion:** 2021-12-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04969068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04969068, "The Median Effective Dose of Remimazolam for Duodenoscopy Insertion During ERCP With Alfentanil 10µg/kg". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04969068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*